Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Reviews Getting NDA-Style Communication Enhancements

Executive Summary

Despite its unprecedented workload, FDA's Office of Generic Drugs is getting more chatty at work: the office is changing its policy to allow for phone communications with applicants

You may also be interested in...



ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources

FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said

ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources

FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said

“First Generics” Will Get Expedited ANDA Reviews Under New FDA Policy

FDA's "First Generics" policy sets a priority review goal of six months for ANDAs for which there is no marketed generic equivalent

Related Content

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel